In clinical trials, PCSK-9 inhibitors have been shown to significantly reduce LDL cholesterol levels and to decrease the risk of cardiovascular events, such as heart attacks and strokes.[17,18] However, the long-term effects on cardiovascular outcomes and mortality rates are still being studied. Here, PCSK9 is linked to myocardial infarction.